MX2021003262A - Metodos de tratamiento. - Google Patents
Metodos de tratamiento.Info
- Publication number
- MX2021003262A MX2021003262A MX2021003262A MX2021003262A MX2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment methods
- methods
- cancer
- compositions
- tumor antigens
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente se proporcionan métodos y composiciones para identificar antígenos tumorales de linfocitos humanos y para tratar sujetos que tienen cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737862P | 2018-09-27 | 2018-09-27 | |
PCT/US2019/053669 WO2020069452A1 (en) | 2018-09-27 | 2019-09-27 | Treatment methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003262A true MX2021003262A (es) | 2021-07-15 |
Family
ID=69953226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003262A MX2021003262A (es) | 2018-09-27 | 2019-09-27 | Metodos de tratamiento. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230041057A1 (es) |
EP (1) | EP3856207A4 (es) |
JP (1) | JP2022502433A (es) |
KR (1) | KR20210091137A (es) |
CN (1) | CN113194967A (es) |
AU (1) | AU2019351273A1 (es) |
BR (1) | BR112021005596A2 (es) |
CA (1) | CA3113259A1 (es) |
CO (1) | CO2021005207A2 (es) |
EA (1) | EA202190862A1 (es) |
IL (1) | IL281792A (es) |
MX (1) | MX2021003262A (es) |
SG (1) | SG11202102878TA (es) |
WO (1) | WO2020069452A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111491655A (zh) | 2017-08-07 | 2020-08-04 | 加利福尼亚大学董事会 | 用于生成安全细胞治疗剂的平台 |
CN115023270A (zh) * | 2019-11-27 | 2022-09-06 | 迈斯特治疗公司 | 使用调节剂产生肿瘤反应性t细胞组合物的方法 |
CN113278731A (zh) * | 2021-05-12 | 2021-08-20 | 广西医科大学 | 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003265948B8 (en) * | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
ZA200602941B (en) * | 2003-11-13 | 2007-07-25 | Genentech Inc | Screening assays and methods of tumor treatment |
EP1765988B1 (en) * | 2004-05-27 | 2017-09-20 | The Trustees of The University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
EP2327763B1 (en) * | 2005-08-05 | 2018-03-14 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Generation of antigen specific T cells |
JP2010235611A (ja) * | 2010-05-10 | 2010-10-21 | Ortho Mcneil Pharmaceut Inc | 腫瘍の治療のための細胞治療方法 |
WO2015120198A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
TWI742008B (zh) * | 2015-11-02 | 2021-10-11 | 美商健生生物科技公司 | 使用特異性結合cd38之抗體免疫調節及治療固態腫瘤 |
-
2019
- 2019-09-27 WO PCT/US2019/053669 patent/WO2020069452A1/en unknown
- 2019-09-27 EA EA202190862A patent/EA202190862A1/ru unknown
- 2019-09-27 EP EP19864650.7A patent/EP3856207A4/en active Pending
- 2019-09-27 US US17/280,498 patent/US20230041057A1/en not_active Abandoned
- 2019-09-27 CN CN201980075999.7A patent/CN113194967A/zh active Pending
- 2019-09-27 SG SG11202102878TA patent/SG11202102878TA/en unknown
- 2019-09-27 KR KR1020217012709A patent/KR20210091137A/ko unknown
- 2019-09-27 MX MX2021003262A patent/MX2021003262A/es unknown
- 2019-09-27 BR BR112021005596-7A patent/BR112021005596A2/pt not_active Application Discontinuation
- 2019-09-27 AU AU2019351273A patent/AU2019351273A1/en active Pending
- 2019-09-27 CA CA3113259A patent/CA3113259A1/en active Pending
- 2019-09-27 JP JP2021517298A patent/JP2022502433A/ja active Pending
-
2021
- 2021-03-24 IL IL281792A patent/IL281792A/en unknown
- 2021-04-22 CO CONC2021/0005207A patent/CO2021005207A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021005207A2 (es) | 2021-07-30 |
EP3856207A1 (en) | 2021-08-04 |
AU2019351273A1 (en) | 2021-05-20 |
WO2020069452A1 (en) | 2020-04-02 |
BR112021005596A2 (pt) | 2021-06-29 |
CN113194967A (zh) | 2021-07-30 |
SG11202102878TA (en) | 2021-04-29 |
JP2022502433A (ja) | 2022-01-11 |
US20230041057A1 (en) | 2023-02-09 |
EA202190862A1 (ru) | 2021-07-07 |
KR20210091137A (ko) | 2021-07-21 |
IL281792A (en) | 2021-05-31 |
EP3856207A4 (en) | 2022-11-16 |
CA3113259A1 (en) | 2020-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011148A (es) | Metodos de tratamiento. | |
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
NZ725487A (en) | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof | |
MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
MX2021003262A (es) | Metodos de tratamiento. | |
MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2020006297A (es) | Variantes de cd19. | |
WO2017040666A3 (en) | Combination therapy for treatment of disease | |
ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
MX2021003265A (es) | Metodos de tratamiento. | |
EP3371211A4 (en) | METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT | |
SA521422250B1 (ar) | أجسام مضادة للبيريوستين واستخداماتها | |
MX2022014180A (es) | Metodos, terapias y usos para tratar cancer. |